Оценка результатов сравнительного исследования эффективности и безопасности применения комплекса «Фосфалит®» у пациентов с фосфатной формой мочекаменной болезни.

Abstract

Introduction. Urolithiasis is a widespread disease. The percentage of phosphate stones reaches up to 35% of all cases of all kidney stones. Patients with phosphate stones and with various urinary catheters in particular are a complex category of patients requiring the close attention of doctors. Phosphate urolithiasis clinical patterns create a constant search for various oral therapy options. The purpose of this study is to evaluate the effectiveness of the Phosphalit complex as an optional drug for metabolic disorder correction in phosphate kidney stones. Materials and methods. The prospective randomized control study included 135 patients, 131 people returned for a second visit. All the patients were divided in 4 groups: patients with phosphate urolithiasis who received Phosphalit® on a regular basis, 2 capsules 2 times a day; patients with phosphate urolithiasis who received general recommendations for lifestyle and diet changes; patients with phosphate urolithiasis against the back- ground of existing permanent urinary catheters, receiving the drug Phosphalit® on a regular basis, 2 capsules 2 times a day; patients with phosphate urolithiasis on the background of permanent urinary catheters, who received general recommendations for lifestyle and diet changes. The duration of observation and intervention was 90 days. Results. The total effectiveness of Phosphalit® in reducing the level of phosphates in the blood in both groups of patients (with and without catheters) was 90.1%, and in reducing the excretion of phosphates in urine – 93.3%. The dynamics of the degree of crystalluria and the stone size also showed positive dynamics in all the studied groups. Conclusions. Phosphalit® is an effective and safe remedy in the treatment of the phosphate urolithiasis, including patients with urinary catheters.